<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1296">
  <stage>Registered</stage>
  <submitdate>19/05/2006</submitdate>
  <approvaldate>31/05/2006</approvaldate>
  <actrnumber>ACTRN12606000218594</actrnumber>
  <trial_identification>
    <studytitle>A Trial of MitoQ for the Treatment of People with Parkinson's Disease</studytitle>
    <scientifictitle>A Double-Blind, Prospective, Randomized Comparison of 2 Doses of MitoQ and Placebo for the Treatment of Patients with Parkinsons Disease</scientifictitle>
    <utrn />
    <trialacronym>Protect</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Parkinson's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>40 mg mitoquinone, 80 mg mitoquinone administered orally one daily for 12 months</interventions>
    <comparator>Placebo administered orally one daily for 12 months</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in total UPDRS (Unified Parkinson's Disease Rating Scale) score at end of treatment period compared with baseline</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>UPDRS sub-scores (mental, motor and Activities of Daily Living)</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified Hoehn and Yahr Scale score</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Schwab and England Scale score (observer and subject)</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mini-Mental State Examination score</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Timed tapping score</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disability sufficient to require treatment with antiparkinsonion medication</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma concentrations of mitoquinone</outcome>
      <timepoint>Comparison of baseline and final visit assessments</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Informed consent. 2. Diagnosis of PD (2 or more of bradykinesia; rest tremor, rigidity). 3. Adequate contraceptive measures (females).</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Malignancy within last 2 years2. Pregnancy &amp; breast-feeding3. Treatment with any anti-PD drugs within 30 days of enrolment4. Prior treatment with anti-PD medication exceeding 42 days in total5. Medication-induced PD/PD not of idiopathic origin6. CoQ10/idebenone doses of 300mg/day or higher within 120 days, &gt;25mg/day within 7 days of enrolment7. Methylphenidate HCl, neuroleptics, reserpine, amphetamines, selegeline or MAOIs within 6 months of enrolment8. CNS medications at unstable doses within 60 days of enrolment9. Dietary supplements &gt; 5 x RDI10. Hypersensitivity to CoQ10, idebenone or any components of the study drug 11. Unable to swallow12. Diseases with features of PD 13. Seizure(s) within 12 months prior to enrolment14. UPDRS tremor score of 415. Hamilton Depression Rating Scale score &gt; 1016. History of stroke17. Requirement for dopaminergic drugs18. Modified Hoehn &amp; Yahr score &gt; 2.519. History of brain surgery for Parkinsons disease20. History of structural brain disease / congenital brain abnormality21. History of ECT22. Any other clinically significant medical or psychiatric condition or lab abnormality23. Enrolment in any other pharmacological study within 30 days of enrolment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone/fax</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>19/05/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Antipodean Pharmaceuticals, Inc</primarysponsorname>
    <primarysponsoraddress>1700 Montgomery Street, Suite 209
San Francisco CA 94111, USA</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Antipodean Pharmaceuticals, Inc.</fundingname>
      <fundingaddress>1700 Montgomery Street, Suite 209
San Francisco CA 94111, USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Eligible participants will be randomised to study medication and treated for 12 months. The researcher will randomise the patient using a centralised phone system.  The researcher, participant and sponsor will be blinded to the study treatment.  Safety &amp; efficacy reviews occur at the 1, 2, 3, 6, 9 &amp; 12 month timepoints with a 28 day post-study follow-up visit for safety.  Withdrawal criteria include unacceptable AEs, participant choice, investigator decision, non-compliance with study drug &amp; requirement for anti-PD medication including dopaminergic drugs.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multiregion Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
1 - 3 The Terrace
PO Box 5013
Wellington</ethicaddress>
      <ethicapprovaldate>10/05/2006</ethicapprovaldate>
      <hrec>MEC/06/03/033</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service (Westmead Campus) Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office, Clinical Sciences
Westmead Hospital Campus
Westmead NSW 2145</ethicaddress>
      <ethicapprovaldate>28/06/2006</ethicapprovaldate>
      <hrec>HS/pmeHREC2006/5/4 20(2325)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Women?s Hospital &amp; Health Service Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Brisbane and Women's Hospital Butterfield Street 
Herston QLD 4029</ethicaddress>
      <ethicapprovaldate>19/06/2006</ethicapprovaldate>
      <hrec>2006/068</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Harold Stokes Building, 
Austin Health
145 Studely Road 
HEIDELBERG VIC 3084</ethicaddress>
      <ethicapprovaldate />
      <hrec>14/07/2006</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>MTQ-PD-001,</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Barry Snow</name>
      <address>Department of Neurology
Auckland City Hospital
Private Bag 92 189
Park Road
Grafton Auckland</address>
      <phone>+64 9 3074949</phone>
      <fax>+64 9 3074924</fax>
      <email>bsnow@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fiona Rolfe</name>
      <address>Antipodean Pharmaceuticals (NZ) Ltd, PO Box 106734, Auckland 1143, New Zealand</address>
      <phone>+64 9 379 8245</phone>
      <fax>+64 9 379 8244</fax>
      <email>antipodean@antipodeanpharma.com</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Fiona Rolfe</name>
      <address>Antipodean Pharmaceuticals (NZ) Ltd, PO Box 106734, Auckland 1143, New Zealand</address>
      <phone>+64 9 379 8245</phone>
      <fax>+64 9 379 8244</fax>
      <email>frolfe@antipodeanpharma.com</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>